BioCina and CelluTx Partner for Next-Gen mcDNA Production

• BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), has secured exclusive rights to use CelluTx’s recombination-based plasmid system (RBPS) technology with its CDMO clients.

• The RBPS technology offers several advantages over older mcDNA technologies, including process scalability, high recombination efficiency, higher yields, simpler purification processes, and the ability to produce larger minicircles.

BioCina Pty Ltd. has announced an exclusive agreement to utilise CelluTx’s recombination-based plasmid system (RBPS) technology with its CDMO clients. The RBPS technology is a novel method for minicircle DNA (mcDNA) production, which involves site-specific recombination within a bacterial host. This process separates the minicircle containing the gene of interest from the rest of the plasmid backbone.

The RBPS technology offers several advantages over older mcDNA technologies. These include process scalability, exceptionally high recombination efficiency, higher yields, and simpler purification processes due to the clear separation of minicircles from miniplasmids. It also allows for the production of larger minicircles that can accommodate complex gene cassettes.

The streamlined structure of the mcDNA leads to enhanced and prolonged transgene expression, making it less immunogenic and safer for in vivo use. These benefits make RBPS a promising approach for advancing mcDNA production and expanding its potential applications in cell and gene therapies and other advanced therapeutics.

Mark Womack, CEO of BioCina, said, “We are pleased to announce our partnership with CelluTx enabling BioCina to exclusively provide this innovative technology to our clients around the world. We have already witnessed great success in utilising it within our client portfolio and eagerly anticipate advancing many other client programs with the technology.”

Maurits Geerlings, CEO of CelluTx, added, “We are very pleased to engage with BioCina for the worldwide deployment of the RBPS minicircle DNA technology. BioCina has proven capabilities and the highest commitment to its customers, which has been fundamental to our partnering with BioCina.”